µå·¯±×ÀÎÆ÷¸ÞÀÎ
 

»óº´Äڵ忡 µû¸¥ »óº´¸íÀ» È®ÀÎ ÇϽǼö ÀÖ½À´Ï´Ù.  
»óº´ÄÚµå ÇÑ±Û»óº´¸í ¿µ¹®»óº´¸í
Y549 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ¹«±â¿°·ù Mineral salts, NEC causing adverse effects in therapeutic use
Y55 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÆòȰ±Ù ¹× °ñ°Ý±Ù°ú È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â Á¦Á¦ Agents primarily acting on smooth and skeletal muscles and the respiratory system causing adverse effects in therapeutic use
Y550 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀڱüöÃ༺ ¾à¹° Oxytocic drugs causing adverse effects in therapeutic use
Y550 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¸Æ°¢¾ËÄ®·ÎÀ̵å Ergot alkaloids causing adverse effects in therapeutic use
Y551 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °ñ°Ý±ÙÀÌ¿ÏÁ¦[½Å°æ±ÙÀ° Â÷´ÜÁ¦] Skeletal muscle relaxants [neuromusclular blocking agents]causing adverse effects in therapeutic use
Y552 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ±ÙÀ°¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ Other and unspecified agents primarily acting on muscles causing adverse effects in therapeutic use
Y553 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±âħ¾à Antitussives causing adverse effects in therapeutic use
Y554 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¡·¡¾à Expectorants causing adverse effects in therapeutic use
Y555 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â °¨±â¾à Anti-common-cold drugs causing adverse effects in therapeutic use
Y556 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº Ç×õ½ÄÁ¦ Antiasthmatics, NEC causing adverse effects in therapeutic use
Y556 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ¾Æ¹Ì³ëÇʸ° Aminophylline causing adverse effects in therapeutic use
Y556 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â »ìºÎŸ¸ô Salbutamol causing adverse effects in therapeutic use
Y556 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ƽ¿ÀºÎ·Î¹Î Theobromine causing adverse effects in therapeutic use
Y556 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Å׿ÀÇʸ° Theophylline causing adverse effects in therapeutic use
Y557 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î È£Èí°èÅë¿¡ ÀÛ¿ëÇÏ´Â ±âŸ ¹× »ó¼¼ºÒ¸íÀÇ Á¦Á¦ Other and unspecified agents primarily acting on the respiratory system causing adverse effects in therapeutic use
Y56 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ÀÏÂ÷ÀûÀ¸·Î ÇǺΠ¹× Á¡¸·¿¡ ÀÛ¿ëÇÏ´Â ¾àÁ¦¿Í ¾È°úÀû, À̺ñÀÎÈİúÀû ¹× Ä¡°úÀû Á¦Á¦ Agents primarily affecting skin and mucous membrane and ophthalmological, otorhinolaryngological and dental drugs causing adverse effects in therapeutic use
Y56 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼ÒÀûÀ¸·Î »ç¿ëµÈ ±Û·çÄÚÄÚ¸£Æ¼ÄÚÀ̵å Glucocorticoids, topically used causing adverse effects in therapeutic use
Y560 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ´Þ¸® ºÐ·ùµÇÁö ¾ÊÀº ±¹¼Ò Ç×Áø±ÕÁ¦, Ç×°¨¿°Á¦ ¹× Ç׿°ÁõÁ¦ Local antifungal, anti-infective and anti-inflammatory drugs, NEC causing adverse effects in therapeutic use
Y561 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â Ç×°¡·Á¿òÁ¦ Antipruritics causing adverse effects in therapeutic use
Y562 Ä¡·á½Ã À¯ÇØÀÛ¿ëÀ» ³ªÅ¸³»´Â ±¹¼Ò¼ö·ÅÁ¦ ¹× ±¹¼Ò¼¼Á¤Á¦ Local astringents and local detergents causing adverse effects in therapeutic use
1911  1912  1913  1914  1915  1916  [1917] 1918  1919  1920